Companies / Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated

Nasdaq: PRLDCIK 1678660WILMINGTON, DE

Financials · FY2025

Revenue$12.14M
Net income$-99.50M
Total debt—
Cash$26.33M
Diluted EPS$-1.29
Shares outstanding79.8M

Ownership

79.8M shares outstanding · as of Aug 6, 2026
1.4%Insiders
Ownership
Insiders1.41%1,126,126
10%+ / strategic8.11%6,475,882
Institutions27.56%21,990,311
Public float62.92%50,211,166

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 20

View all →
Insider% of sharesShares
RA Capital Management, L.P.10% owner
8.11%6,475,882
Orbimed Advisors LLCDirector · 10% owner
1.41%1,126,126
667, L.P.Director · 10% owner
——
Baker Bros. Advisors (GP) LLCDirector · 10% owner
——
Baker Bros. Advisors LPDirector · 10% owner
——
Baker Brothers Life Sciences LPDirector · 10% owner
——
Baker FelixDirector · 10% owner
——
Baker JulianDirector · 10% owner
——
Brusky Sean P.Chief Business Officer
——
Combs AndrewChief Chemistry Officer
——

Institutional holders 51

View all →
HolderValue% of shares
Orbimed Advisors LLC$37.31M13.67%
Baker Bros. Advisors LP$34.62M12.69%
BlackRock, Inc.$9.58M2.25%
Vanguard Group Inc$4.10M1.77%
Two Sigma Investments, LP$3.16M1.16%
Kynam Capital Management, LP$2.29M0.99%
State Street Corporation$2.29M0.54%
Boxer Capital Management, LLC$1.62M2.64%
Millennium Management LLC$1.31M0.48%
Marshall Wace, LLP$1.23M0.45%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Apr 21, 2026Orbimed Advisors LLC
Director
BuyCommon Stock$7.50M+1.7M
+16.69%
11,808,945
14.80% of shares
high
Apr 21, 2026Orbimed Advisors LLC
Director
BuyCommon Stock$5.00M+1.1M
1,126,126
1.41% of shares
high
Apr 27, 2026RA Capital Management, L.P.
10% owner
OtherPre-Funded Warrants (Right to Buy)—+1.4M
1,407,000
1.76% of shares
low
Apr 27, 2026RA Capital Management, L.P.
10% owner
OtherCommon Stock—-1.4M
-17.85%
6,475,882
8.11% of shares
low
Jun 9, 2026Friedman Paul a
Director
GrantDirector Stock Option (Right to Buy)—+38K
38,000
0.05% of shares
low
Jun 9, 2026Baker Bros. Advisors LP
Director
GrantNon-Qualified Stock Option (right to buy)—+38K
38,000
0.05% of shares
low
Jun 9, 2026Baker Bros. Advisors LP
Director
GrantNon-Qualified Stock Option (right to buy)—+38K
38,000
0.05% of shares
low
Apr 21, 2026Baker Bros. Advisors LP
Director
BuyWarrants to purchase Common Stock—+2.1M
+11.90%
20,105,994
25.19% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Vaddi KrishnaPassive13G/A———
RA Capital Management, L.P.Passive13G———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
PRLD——74065P101—